The PDUFA gets bumped 3 months but the advisory board is still going to weigh in on DCTH's application? Seems a bit odd....
The previously announced Oncologic Drugs Advisory Committee meeting remains unchanged, and the FDA will convene its ODAC Panel on Thursday, May 2, 2013 for review of the Company's NDA.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.